Pluristem Therapeutics, Inc. (PSTI) Monday said independent researchers from the Queensland Lung Transplant Service at the University of Queensland, Australia demonstrated that, following infusion of Pluristem's PLX cells or Placental eXpanded cells in a human lung model of pulmonary arterial hypertension or PAH, blood flows were maintained and no adverse hemodynamic effects were noted.
Commenting on the development, Zami Aberman, Pluristem's Chairman and CEO said, "We are pleased that independent researchers were able to demonstrate the safety of our PLX-PAD cells in this unique human lung model designed to bridge the gap between data obtained from animals and data needed to commence human studies. We look forward to the initiation of Phase I human studies for this important indication."
On June 20, 2011 United Therapeutics and Pluristem entered into a licensing agreement pursuant to which United Therapeutics will develop, market and sell Pluristem's PLX-PAD cells for PAH.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.